These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 23979733)

  • 1. Lack of pharmacokinetic interaction between rilpivirine and integrase inhibitors dolutegravir and GSK1265744.
    Ford SL; Gould E; Chen S; Margolis D; Spreen W; Crauwels H; Piscitelli S
    Antimicrob Agents Chemother; 2013 Nov; 57(11):5472-7. PubMed ID: 23979733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of fosamprenavir-ritonavir on the pharmacokinetics of dolutegravir in healthy subjects.
    Song I; Borland J; Chen S; Peppercorn A; Wajima T; Piscitelli SC
    Antimicrob Agents Chemother; 2014 Nov; 58(11):6696-700. PubMed ID: 25155604
    [TBL] [Abstract][Full Text] [Related]  

  • 3. No clinically significant pharmacokinetic interactions between dolutegravir and daclatasvir in healthy adult subjects.
    Ross LL; Song IH; Arya N; Choukour M; Zong J; Huang SP; Eley T; Wynne B; Buchanan AM
    BMC Infect Dis; 2016 Jul; 16():347. PubMed ID: 27450277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of etravirine on the pharmacokinetics of the integrase inhibitor S/GSK1265744.
    Ford SL; Gould E; Chen S; Lou Y; Dumont E; Spreen W; Piscitelli S
    Antimicrob Agents Chemother; 2013 Jan; 57(1):277-80. PubMed ID: 23114768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of prednisone on the pharmacokinetics of the integrase inhibitor dolutegravir.
    Song IH; Borland J; Chen S; Savina P; Peppercorn AF; Piscitelli S
    Antimicrob Agents Chemother; 2013 Sep; 57(9):4394-7. PubMed ID: 23817375
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of enzyme inducers efavirenz and tipranavir/ritonavir on the pharmacokinetics of the HIV integrase inhibitor dolutegravir.
    Song I; Borland J; Chen S; Guta P; Lou Y; Wilfret D; Wajima T; Savina P; Peppercorn A; Castellino S; Wagner D; Hosking L; Mosteller M; Rubio JP; Piscitelli SC
    Eur J Clin Pharmacol; 2014 Oct; 70(10):1173-9. PubMed ID: 25146692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of carbamazepine on dolutegravir pharmacokinetics and dosing recommendation.
    Song I; Weller S; Patel J; Borland J; Wynne B; Choukour M; Jerva F; Piscitelli S
    Eur J Clin Pharmacol; 2016 Jun; 72(6):665-70. PubMed ID: 26898568
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Two-Way Steady-State Pharmacokinetic Interaction Study of Doravirine (MK-1439) and Dolutegravir.
    Anderson MS; Khalilieh S; Yee KL; Liu R; Fan L; Rizk ML; Shah V; Hussaini A; Song I; Ross LL; Butterton JR
    Clin Pharmacokinet; 2017 Jun; 56(6):661-669. PubMed ID: 27699622
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Durability of rilpivirine-based versus integrase inhibitor-based regimens in a large cohort of naïve HIV-infected patients starting antiretroviral therapy.
    Gagliardini R; Gianotti N; Maggiolo F; Cozzi-Lepri A; Antinori A; Nozza S; Lapadula G; De Luca A; Mussini C; Gori A; Saracino A; Andreoni M; Monforte AD;
    Int J Antimicrob Agents; 2021 Oct; 58(4):106406. PubMed ID: 34293454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics, safety, and tolerability with repeat doses of GSK1265744 and rilpivirine (TMC278) long-acting nanosuspensions in healthy adults.
    Spreen W; Williams P; Margolis D; Ford SL; Crauwels H; Lou Y; Gould E; Stevens M; Piscitelli S
    J Acquir Immune Defic Syndr; 2014 Dec; 67(5):487-92. PubMed ID: 25473882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and pharmacokinetics of dolutegravir in pregnant mothers with HIV infection and their neonates: A randomised trial (DolPHIN-1 study).
    Waitt C; Orrell C; Walimbwa S; Singh Y; Kintu K; Simmons B; Kaboggoza J; Sihlangu M; Coombs JA; Malaba T; Byamugisha J; Amara A; Gini J; Else L; Heiburg C; Hodel EM; Reynolds H; Mehta U; Byakika-Kibwika P; Hill A; Myer L; Lamorde M; Khoo S
    PLoS Med; 2019 Sep; 16(9):e1002895. PubMed ID: 31539371
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of atazanavir and atazanavir/ritonavir on the pharmacokinetics of the next-generation HIV integrase inhibitor, S/GSK1349572.
    Song I; Borland J; Chen S; Lou Y; Peppercorn A; Wajima T; Min S; Piscitelli SC
    Br J Clin Pharmacol; 2011 Jul; 72(1):103-8. PubMed ID: 21342217
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of dolutegravir in HIV-seronegative subjects with severe renal impairment.
    Weller S; Borland J; Chen S; Johnson M; Savina P; Wynne B; Wajima T; Peppercorn AF; Piscitelli SC
    Eur J Clin Pharmacol; 2014 Jan; 70(1):29-35. PubMed ID: 24096683
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pharmacokinetic interactions].
    Arazo Garcés P; de los Santos Gil I
    Enferm Infecc Microbiol Clin; 2013 Jun; 31 Suppl 2():12-9. PubMed ID: 24252529
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative efficacy, safety and durability of dolutegravir relative to common core agents in treatment-naïve patients infected with HIV-1: an update on a systematic review and network meta-analysis.
    Nickel K; Halfpenny NJA; Snedecor SJ; Punekar YS
    BMC Infect Dis; 2021 Feb; 21(1):222. PubMed ID: 33637050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relative Bioavailability of Dolutegravir (DTG) and Emtricitabine/Tenofovir Alafenamide Fumarate (F/TAF) Administered as Paediatric Tablet Formulations in Healthy Volunteers.
    Bevers LAH; Kamphuis AEM; van der Wekken-Pas LCW; Leisegang R; Burger DM; Colbers A
    Clin Pharmacokinet; 2024 May; 63(5):721-728. PubMed ID: 38573477
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and tolerability of dolutegravir/lamivudine versus dolutegravir/rilpivirine in switching from a three-drug regimen based on nonnucleoside reverse transcriptase inhibitors: A retrospective cohort study.
    Lagi F; Giacomelli A; Borghi V; Ciccullo A; Taramasso L; Madeddu G; D'Ettorre G; Giacometti A; Ducci F; De Vito A; Pincino R; Di Giambenedetto S; Mussini C; Antinori S; Sterrantino G
    J Med Virol; 2023 Oct; 95(10):e29149. PubMed ID: 37805832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of boceprevir and telaprevir on the pharmacokinetics of dolutegravir.
    Johnson M; Borland J; Chen S; Savina P; Wynne B; Piscitelli S
    Br J Clin Pharmacol; 2014 Nov; 78(5):1043-9. PubMed ID: 24838177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety, tolerability and pharmacokinetics of rilpivirine following administration of a long-acting formulation in healthy volunteers.
    Verloes R; Deleu S; Niemeijer N; Crauwels H; Meyvisch P; Williams P
    HIV Med; 2015 Sep; 16(8):477-84. PubMed ID: 25988676
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bioequivalence and Food Effect Assessment of 2 Fixed-Dose Combination Formulations of Dolutegravir and Lamivudine.
    Dumitrescu TP; Peddiraju K; Fu C; Bakshi K; Yu S; Zhang Z; Tenorio AR; Spancake C; Joshi S; Wolstenholme A; Adkison K
    Clin Pharmacol Drug Dev; 2020 Feb; 9(2):189-202. PubMed ID: 31724343
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.